Ensuring trial validity by data quality assurance and diversification of monitoring methods.
Errors in the design, the conduct, the data collection process, and the analysis of a randomized trial have the potential to affect not only the safety of the patients in the trial, but also, through the introduction of bias, the safety of future patients. Trial monitoring, defined broadly to includ...
| Publicado en: | Clinical Trials Vol. 5; no. 1; pp. 49 - 56 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Sage Publications, Ltd.
2008
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105668642&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105668642 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17407745 AB6 jtl: Clinical Trials issn: 17407745 maglogo: N pubinfo: dt: 2008 vid: 5 iid: 1 pid: 33180 pub: Sage Publications, Ltd. place: <Blank> artinfo: ui: 105668642 2010056045 NLM18283080 105668642 ppf: 49 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Ensuring trial validity by data quality assurance and diversification of monitoring methods. aug: au: Baigent C Harrell FE Buyse M Emberson JR Altman DG affil: Clinical Trial Service Unit & Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF. colin.baigent@ctsu.ox.ac.uk sug: subj: Clinical Trials Methods Clinical Trials Bias (Research) Quality Control (Technology) Risk Assessment Study Design ab: Errors in the design, the conduct, the data collection process, and the analysis of a randomized trial have the potential to affect not only the safety of the patients in the trial, but also, through the introduction of bias, the safety of future patients. Trial monitoring, defined broadly to include methods of oversight which begin when the study is designed and continue until it is reported in a publication, has a role to play in eliminating such errors. On-site monitoring can be extremely inefficient for the identification of errors most likely to compromise patient safety or bias study results. However, a variety of other monitoring strategies offer alternatives to on-site monitoring. Each new trial should conduct a risk assessment to identify the optimal means of monitoring, taking into account the likely sources of error, their consequences for patients, the study's validity, and the available resources. Trial management committees should consider central statistical monitoring a key aspect of such monitoring. The systematic application of this approach would be likely to lead to tangible benefits, and resources that are currently wasted on inefficient on-site monitoring could be diverted to increasing trial sample sizes or conducting more trials. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|